What is the price-to-earnings ratio of BB Biotech?
The price-earnings ratio of BB Biotech is currently 17.53.
BB Biotech P/S 2024
BB Biotech P/S
17.53
Ticker
BION.SW
ISIN
CH0038389992
WKN
A0NFN3
As of Jun 15, 2024, BB Biotech's P/S ratio stood at 17.53, a 301.14% change from the 4.37 P/S ratio recorded in the previous year.
The BB Biotech P/S history
BB Biotech Aktienanalyse
What does BB Biotech do?
BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding BB Biotech's P/S Ratio
BB Biotech's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing BB Biotech's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating BB Biotech's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in BB Biotech’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about BB Biotech Stock
How has the price-earnings ratio of BB Biotech changed compared to last year?
The price-to-earnings ratio of BB Biotech has increased by 301.14% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of BB Biotech high compared to other companies?
Yes, the price-to-earnings ratio of BB Biotech is high compared to other companies.
How does an increase in the price-earnings ratio of BB Biotech affect the company?
An increase in the price-earnings ratio of BB Biotech would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of BB Biotech affect the company?
A decrease in the price-earnings ratio of BB Biotech would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of BB Biotech?
Some factors that influence the price-earnings ratio of BB Biotech are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does BB Biotech pay?
Over the past 12 months, BB Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BB Biotech is expected to pay a dividend of 0 CHF.
What is the dividend yield of BB Biotech?
The current dividend yield of BB Biotech is .
When does BB Biotech pay dividends?
BB Biotech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BB Biotech?
BB Biotech paid dividends every year for the past 0 years.
What is the dividend of BB Biotech?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is BB Biotech located?
BB Biotech is assigned to the '-' sector.
Wann musste ich die Aktien von BB Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BB Biotech from 6/15/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/15/2024.
When did BB Biotech pay the last dividend?
The last dividend was paid out on 6/15/2024.
What was the dividend of BB Biotech in the year 2023?
In the year 2023, BB Biotech distributed 0 CHF as dividends.
In which currency does BB Biotech pay out the dividend?
The dividends of BB Biotech are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BB Biotech stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von BB Biotech
Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.